Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Catawba River Capital

Catawba River Capital boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,279 shares of the biopharmaceutical company’s stock after purchasing an additional 383 shares during the quarter. Regeneron Pharmaceuticals comprises approximately 3.9% of Catawba River Capital’s investment portfolio, making the stock its 13th largest position. Catawba River Capital’s holdings in Regeneron Pharmaceuticals were worth $6,610,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Rakuten Securities Inc. raised its position in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the last quarter. FSA Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at about $26,000. Fairfield Financial Advisors LTD acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $37,000. Truvestments Capital LLC purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $39,000. Finally, Valley Wealth Managers Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $49,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 2.8 %

Shares of NASDAQ REGN opened at $690.36 on Tuesday. The business has a 50-day moving average of $715.81 and a two-hundred day moving average of $909.02. The company has a market capitalization of $75.86 billion, a price-to-earnings ratio of 18.03, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 4.46.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $11.86 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.51%. The ex-dividend date is Thursday, February 20th.

Analyst Ratings Changes

REGN has been the subject of several recent research reports. Robert W. Baird cut their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price for the company. Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Finally, Bank of America reaffirmed an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.